J. Goldman & Co’s Neos Therapeutics, Inc NEOS Stock Holding History

J. Goldman & Co’s Portfolio NEOS Stock Details NEOS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-278,000	Closed	-$2.84M	–	477
2017 Q4	$2.84M	Buy	+278,000	New	+$2.67M	0.15%	167

Other funds holding NEOS

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

J. Goldman & Co's NEOS Position: Q2 2019 in Review

J. Goldman & Co sold out of Neos Therapeutics, Inc (NEOS) in Q2 2019, closing a stake of 120,000 shares — an estimated $313K sold.

J. Goldman & Co first reported a position in NEOS in Q2 2017 and held it in 8 quarters. The position peaked at $10.7M in Q2 2018. 58 funds tracked by Wall St. Rank hold NEOS as of Q2 2019.

J. Goldman & Co reported no remaining Neos Therapeutics, Inc position as of Q2 2019 after selling out during the quarter.
J. Goldman & Co sold 120,000 Neos Therapeutics, Inc shares in Q2 2019, an estimated $313K.
J. Goldman & Co first reported a position in Neos Therapeutics, Inc in Q2 2017 and held it in 8 quarters.
J. Goldman & Co's Neos Therapeutics, Inc position peaked at $10.7M in Q2 2018.
58 funds tracked by Wall St. Rank held Neos Therapeutics, Inc as of Q2 2019.

Based on J. Goldman & Co's 13F filing for Q2 2019, filed 14 Aug 2019.